In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ultralife has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqGM:ULBI - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2025	179	3	14	17	N/A
3/31/2025	173	5	18	20	N/A
12/31/2024	164	6	15	17	N/A
9/30/2024	165	9	14	16	N/A
6/30/2024	169	10	8	10	N/A
3/31/2024	169	10	1	3	N/A
12/31/2023	159	7	-1	2	N/A
9/30/2023	150	4	0	2	N/A
6/30/2023	144	3	0	3	N/A
3/31/2023	133	0	-1	1	N/A
12/31/2022	132	0	-3	-1	N/A
9/30/2022	119	-1	-10	-8	N/A
6/30/2022	108	-1	-8	-6	N/A
3/31/2022	103	-1	-5	-3	N/A
12/31/2021	98	0	2	4	N/A
9/30/2021	103	3	5	9	N/A
6/30/2021	106	4	17	20	N/A
3/31/2021	108	5	23	26	N/A
12/31/2020	108	5	19	22	N/A
9/30/2020	110	5	20	23	N/A
6/30/2020	113	5	6	10	N/A
3/31/2020	114	6	-7	-3	N/A
12/31/2019	107	5	-9	-3	N/A
9/29/2019	97	23	-9	-1	N/A
6/30/2019	90	24	-2	5	N/A
3/31/2019	83	23	N/A	11	N/A
12/31/2018	87	25	N/A	11	N/A
9/30/2018	89	9	N/A	11	N/A
7/1/2018	89	9	N/A	5	N/A
4/1/2018	87	8	N/A	4	N/A
12/31/2017	86	8	N/A	7	N/A
10/1/2017	85	6	N/A	8	N/A
7/2/2017	83	6	N/A	12	N/A
4/2/2017	84	5	N/A	13	N/A
12/31/2016	82	4	N/A	8	N/A
9/25/2016	80	2	N/A	5	N/A
6/26/2016	79	2	N/A	3	N/A
3/27/2016	78	3	N/A	3	N/A
12/31/2015	76	3	N/A	9	N/A
9/27/2015	77	3	N/A	11	N/A
6/28/2015	74	2	N/A	7	N/A
3/29/2015	70	0	N/A	4	N/A
12/31/2014	66	-2	N/A	4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ULBI's forecast earnings growth is above the savings rate (3.3%).

Earnings vs Market: Insufficient data to determine if ULBI's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ULBI's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ULBI's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ULBI's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ULBI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/14 01:24
End of Day Share Price	2025/11/14 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ultralife Corporation is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joshua Sullivan	Benchmark Company
Ted Kundtz	Needham & Company
Matthew Paul	Sidoti & Company, LLC

Ultralife Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 7.7% to US$12.00

Consensus revenue estimates increase by 12%

Price target increased to US$12.00

Consensus revenue estimates fall by 14%

Recent updates

Ultralife Corporation to Report Q3, 2025 Results on Nov 18, 2025

Ultralife Corporation announced delayed 10-Q filing

Ultralife Corporation's (NASDAQ:ULBI) Share Price Is Still Matching Investor Opinion Despite 25% Slump

Ultralife Corporation to Report Q2, 2025 Results on Aug 07, 2025

Ultralife (NASDAQ:ULBI) Has A Somewhat Strained Balance Sheet

Ultralife Corporation(NasdaqGM:ULBI) dropped from Russell 2000 Growth-Defensive Index

Ultralife: Recharging Growth With Smart Acquisitions

Ultralife Corporation, Annual General Meeting, Jul 16, 2025

Ultralife Corporation to Report Q1, 2025 Results on May 09, 2025

Ultralife Corporation announced delayed annual 10-K filing

Ultralife Corporation to Report Q4, 2024 Results on Mar 11, 2025

Ultralife Corporation: A High-Risk Stock With Just Enough Upside To Hold

Ultralife Corporation Announces the Appointment of Jeffrey Luke as Chief Marketing Officer and James Pope as Senior Vice President - Sales & Business Development, Battery & Energy Products, Effective January 6, 2025

Lean Productivity And Tactical Acquisitions Propel Future Growth Amid Industry Challenges

Ultralife Corporation to Report Q3, 2024 Results on Nov 08, 2024

Ultralife Corporation (NasdaqGM:ULBI) signed a stock purchase agreement to acquire Electrochem Solutions, Inc. from Integer Holdings Corporation (NYSE:ITGR) for $50 million.

Should You Think About Buying Ultralife Corporation (NASDAQ:ULBI) Now?

Ultralife: I Bought The Dip; Here Comes The Growth

Ultralife's (NASDAQ:ULBI) Earnings Are Weaker Than They Seem

Ultralife Corporation to Report Q2, 2024 Results on Jul 25, 2024

Ultralife Corporation Is Attractive Here

Ultralife Corporation, Annual General Meeting, Jul 16, 2024

Investor sentiment improves as stock rises 17%

Price target decreased by 7.7% to US$12.00

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ultralife Corporation: Ready To Surge

These 4 Measures Indicate That Ultralife (NASDAQ:ULBI) Is Using Debt Reasonably Well

Ultralife Corporation to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: EPS: US$0.44 (vs US$0.007 loss in FY 2022)

Slowing Rates Of Return At Ultralife (NASDAQ:ULBI) Leave Little Room For Excitement

Full year 2023 earnings released: EPS: US$0.44 (vs US$0.007 loss in FY 2022)

Investor sentiment improves as stock rises 15%

Insufficient Growth At Ultralife Corporation (NASDAQ:ULBI) Hampers Share Price

New major risk - Revenue and earnings growth

Ultralife Corporation to Report Q4, 2023 Results on Feb 15, 2024

Independent Chairman recently bought US$111k worth of stock

Independent Chairman recently bought US$181k worth of stock

Independent Chairman recently bought US$99k worth of stock

Investor sentiment deteriorates as stock falls 19%

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Is Now An Opportune Moment To Examine Ultralife Corporation (NASDAQ:ULBI)?

Ultralife Corporation to Report Q3, 2023 Results on Oct 26, 2023

Investor sentiment improves as stock rises 18%

Ultralife (NASDAQ:ULBI) May Have Issues Allocating Its Capital

Independent Chairman recently bought US$112k worth of stock

Investor sentiment improves as stock rises 27%

Consensus revenue estimates increase by 12%

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ultralife Corporation to Report Q2, 2023 Results on Jul 27, 2023

Independent Chairman recently bought US$398k worth of stock

Ultralife (NASDAQ:ULBI) Takes On Some Risk With Its Use Of Debt

Independent Chairman recently bought US$146k worth of stock

Ultralife Corporation, Annual General Meeting, Jul 19, 2023

Independent Chairman recently bought US$117k worth of stock

Full year 2022 earnings released: US$0.007 loss per share (vs US$0.015 loss in FY 2021)

Independent Chairman recently bought US$122k worth of stock

Full year 2022 earnings released: US$0.007 loss per share (vs US$0.015 loss in FY 2021)

Independent Chairman recently bought US$279k worth of stock

Price target increased to US$12.00

Insufficient new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Ultralife (NASDAQ:ULBI) Is Carrying A Fair Bit Of Debt

Ultralife secures $7.5M communications systems contract

Independent Chairman recently bought US$158k worth of stock

Independent Chairman recently bought US$467k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ultralife receives $4.6M communications systems VAA order

Independent Chairman recently bought US$219k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors